CLINICAL TRIAL
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Human Dosimetry of the N-Methyl-d-Aspartate Receptor Ligand (11)C-GMOM.

The methylguanidine derivative (11)C-GMOM ((11)C-labeled N-(2-chloro-3-thiomethylphenyl)-N'-(3-methoxyphenyl)-N'-methylguanidine) has been used successfully to quantify N-methyl-d-aspartate (NMDA) receptor binding in humans. The purpose of the present study was to estimate the (11)C-GMOM radiation dose in healthy humans. Methods: After (11)C-GMOM injection, 3 female and 2 male subjects underwent 10 consecutive whole-body PET scans in approximately 77 min. Seven source organs were defined manually, scaled to a sex-specific reference, and residence times were calculated for input into OLINDA/EXM software. Accepted tissue-weighting factors were used to calculate the effective dose. Results: The mean absorbed radiation doses in source organs ranged from 7.7 μGy·MBq(-1) in the brain to 12.7 μGy·MBq(-1) in the spleen. The effective dose (±SD) was 4.5 ± 0.5 μSv·MBq(-1)Conclusion: The effective dose of (11)C-GMOM is at the lower end of the range seen for other (11)C-labeled ligands, allowing for serial PET scanning in a single subject.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app